Navigation Links
Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting
Date:10/1/2010

POWAY, Calif., Oct. 1 /PRNewswire/ -- Vet-Stem, Inc. announced that Dr. Robert Harman, DVM, MPVM, CEO of Vet-Stem, will present a talk entitled "Stem Cell Therapy: Mechanisms of Action" at the Annual Research Symposium of the American College of Veterinary Surgeons (ACVS) in Seattle, WA, October 21, 2010.  

(Logo: http://photos.prnewswire.com/prnh/20060425/VETSTEMLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20060425/VETSTEMLOGO)

Dr. Harman has presented at more than 40 veterinary and human stem cell conferences since the founding of Vet-Stem in 2002.  The ACVS is the largest veterinary surgical meeting in the world, with over 7,000 attendees from around the globe.  This seminar talk will provide continuing education for veterinarians on the most current research about how stem cells work to provide healing and improvement in quality of life of animals.

As the founder and scientific director of Vet-Stem, Dr. Harman has been at the forefront of development of the practical applications of stem cells in our animal populations and has consulted with a number of human stem cell companies to share these veterinary findings for the benefit of potential therapy for people.

Vet-Stem's clinical team has rapidly developed this market, training over 4,000 veterinarians in the United States alone and providing stem cells for treatment of over 7,000 horses and dogs.  Peer-reviewed publications in the journals Veterinary Therapeutics and the American Journal of Veterinary Research have demonstrated the effectiveness of these types of treatments in horses and dogs.  In addition, Dr. Harman has co-authored two publications on how these stem cells from fat tissue can help treat multiple sclerosis and autoimmune diseases in people.

About Vet-Stem, Inc.

'/>"/>
SOURCE Vet-Stem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
2. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
3. Syndax Pharmaceuticals to Present at BIO Investor Forum
4. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
5. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
6. Oncothyreon to Present at JMP Securities Healthcare Conference
7. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
8. InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMDs TCT Satellite Symposium in Washington DC., Today.
9. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
10. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
11. Boehringer Ingelheim Presents New Phase III Data Evaluating Linagliptin in People with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... SAN DIEGO, May 17, 2011 Verenium Corporation (Nasdaq: ... focused on the development and commercialization of high-performance enzymes, ... by MDB Capital Group at the second annual Bright ...  The Bright Lights Conference is the only conference with ...
... Life Technologies Corporation (NASDAQ: LIFE ... of Gibco® Freedom™ Cell Line Development Kits , a ... media and protocols to bring simplicity and flexibility, eliminating up ... drug development.  These kits make it easier and faster to ...
... May 16, 2011 Masimo ... from a new study published in the American ... hemoglobin (SpHb®) monitoring correlates strongly with invasive laboratory hemoglobin ... and critical care setting and may potentially decrease the ...
Cached Biology Technology:Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 2Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 3Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 4Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 2Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 3Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 4Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 2New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 3New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 4New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 6
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... , PITTSBURGH, Feb. 13, 2014 University of Pittsburgh ... be able to do new tricks., By screening a library ... as a treatment for a rare type of cancer, UPCI ... try if the cancer becomes resistant to standard drug treatment., ...
... Children,s Hospital of Philadelphia (CHOP) have developed a ... encode HLA molecules. The test relies on faster, ... leukocyte antigens (HLAs)--complex, highly variable proteins on cell ... The new test may improve transplantation outcomes through ...
... has been named a Fellow of the American Association ... the field of global change ecology, particularly for pioneering ... Models or forecasts similar to those produced for ... the environment will alter an entire ecosystem in the ...
Cached Biology News:Laboratory detective work points to potential therapy for rare, drug-resistant cancer 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 3
... Immunogen: Synthetic peptide derived from the ... mouse dog and orangutang occludin proteins. ... occludin protein. Reactivity: Human (positive ... with rat mouse dog and orangutang ...
...
... protein western blot (WtPAN) is ... specific protein expression in plant ... is included in each blot ... comparison between different western blots. ...
... Water is suitable for use ... by incubating with 0.1% diethylpyrocarbonate ... remove the DEPC.DNase/RNase-Free Distilled WaterDistilled ... in all molecular biology applications. ...
Biology Products: